BrainCells initiates Phase IIa trial for depression with anxiety

The 12 week randomized double-blind, placebo-controlled study will evaluate safety, efficacy and tolerability of BCI-540 to determine whether 80mg given once or three times daily is effective in the treatment of depression with anxiety versus placebo.

Carrolee Barlow, chief scientific officer at BrainCells, said: “Current therapies directly impact serotonin levels causing many unpleasant side effects, however we have shown that BCI-540 directly impacts neurogenesis without affecting serotonin levels. We are excited about the potential of this compound to change the way mood disorders are treated.”